Publications by authors named "Marc Lang"

Claim this Profile
D
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
Maximilien Murone, Anne Vaslin Chessex, Antoine Attinger, Raghuveer Ramachandra, Shankar J Shetty, Marc Lang

Mol Cancer Ther· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.
Frédéric Stauffer, Pascal Furet, Andreas Floersheimer, Marc Lang

Bioorg Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.
Fabienne Baffert, Catherine H Régnier, Alain De Pover, Carole Pissot-Soldermann, Gisele A Tavares, Marc Lang

Mol Cancer Ther· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.
Marc Gerspacher, Pascal Furet, Carole Pissot-Soldermann, Christoph Gaul, Philipp Holzer, Marc Lang

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Entry into a new class of protein kinase inhibitors by pseudo ring design.
Pascal Furet, Giorgio Caravatti, Vito Guagnano, Marc Lang, Thomas Meyer

Bioorg Med Chem Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.
Patricia Imbach, Marc Lang, Carlos García-Echeverría, Vito Guagnano, Maria Noorani

Bioorg Med Chem Lett· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design.
Pascal Furet, Patricia Imbach, Maria Noorani, Juergen Koeppler, Kurt Laumen, Marc Lang

J Med Chem· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.
Pascal Furet, Patricia Imbach, Peter Fuerst, Marc Lang, Maria Noorani

Bioorg Med Chem Lett· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis